Navigation Links
Stimulation of brain region restores consciousness to animals under general anesthesia
Date:7/28/2014

Stimulating one of two dopamine-producing regions in the brain was able to arouse animals receiving general anesthesia with either isoflurane or propofol. In the August issue of Anesthesiology, investigators from Massachusetts General Hospital (MGH) report that rats anesthetized with continuous doses of either agent would move, raise their heads and even stand up in response to electrical stimulation delivered to the ventral tegmental area (VTA). Stimulation of the other major dopamine-releasing area, the substantia nigra, did not induce the animals to wake up.

"Dopamine cells in the VTA are involved in cognition, motivation and reward, while cells in the substantia nigra are important for movement; and our results showed that VTA cells may also be involved in dopamine's known arousal function." explains Ken Solt, MD, of the MGH Department of Anesthesia, Critical Care and Pain Medicine, corresponding author of the report. "Clinically, emergence from general anesthesia is still a passive process during which we just wait for the drugs to wear off and the patient to wake up, a process that can take from a few minutes to an hour or longer. Finding a way to safely arouse patients from anesthesia could both improve operating room efficiency and, even more importantly, may reduce problems such as postoperative delirium and cognitive dysfunction."

Previous studies by Solt and his colleagues have shown that administration of the stimulant drug methylphenidate (Ritalin), known to enhance dopamine-mediated neurotransmission, aroused animals receiving general anesthesia with either inhaled isoflurane or intravenous propofol. An additional study found that activating dopamine receptors also induced reanimation in anesthetized animals, but since older evidence implied that dopamine had no significant role in maintaining wakefulness, the MGH team designed the current study to investigate more directly the role of the brain's major dopamine-releasing structures in emergence from anesthesia.

Tiny electrodes were placed in either the VTA or the substantia nigra of anesthetized rats. Application of a mild electric current stimulates only the tissues directly adjacent to the electrodes, inducing dopamine release. Both groups of animals received continuous isoflurane anesthesia at a dose sufficient to maintain unconsciousness; but while electrical stimulation of the VTA successfully reanimated all animals in which electrodes were correctly positioned, stimulation of the substantia nigra produced no arousal response. Several days later the experiment was repeated using propofol in the animals that had reanimated with VTA stimulation, and again VTA stimulation restored conscious behaviors. A subsequent experiment showed that EEG recordings from anesthetized animals shifted to patterns associated with arousal in response to stimulation of the VTA but not to substantia nigra stimulation.

"These results suggest that the results of our methylphenidate studies were produced by increased dopamine release from the VTA," says Solt, an assistant professor of Ansthesia at Harvard Medical School. "Now we need to investigate the specific role of dopamine neurons and whether activating those cells could help prevent or treat postoperative problems."


'/>"/>

Contact: Terri Ogan
togan@partners.org
617-726-0954
Massachusetts General Hospital
Source:Eurekalert

Related medicine news :

1. Low strength brain stimulation may be effective for depression
2. Deep brain stimulation improves non motor symptoms in Parkinsons disease
3. Tendon stimulation the key to repair in tennis elbow
4. Rice researcher rebooting deep brain stimulation
5. What is being said in the media and academic literature about neurostimulation?
6. Deep brain stimulation for obsessive-compulsive disorder releases dopamine in the brain
7. Precise brain mapping can improve response to deep brain stimulation in depression
8. Functional electrical stimulation improves neuronal regeneration after cerebral infarction
9. New stroke research combines brain stimulation, gait training
10. Knellinger Dental Excellence Brings Laser Gum Disease Treatment for Bone Stimulation and Possible Tooth Loss Prevention
11. Parkinsons disease patients following subthalamic nucleus deep brain stimulation: fully understanding of social maladjustment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... FL (PRWEB) , ... February 22, 2017 , ... Gevir, ... from deer antler velvet, announced its products are coming soon to Amazon.com, the world’s ... and Shelley Thomson as a means to develop an effective natural treatment for Shelley’s ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... its certification exam and eligibility requirements effective with the April 2017 testing period. ... 1995. , “The Care Manager Certified (CMC) exam is periodically re-calibrated to ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a 2012 survey, over ... not filling a prescription because they could not afford to pay for it. ... were 30-60%*. At the same time, hospitals, pharmacies, manufacturers and nursing ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... absorption cannabidiol (CBD) serum, “NANOCALM 300” Microemulsified Hemp Extract. This premier nanoemulsified ... from the mouth into the bloodstream. Far outpacing the absorption speed ...
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... a contract to Quality Insights to help small practices in Delaware, New Jersey, ... Program, established by the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... Feb. 22, 2017  Allergan plc (NYSE: AGN), ... be a Gold sponsor of the Alzheimer,s Foundation ... Tour." This tour commemorates AFA,s15 years of educating ... and programs. The tour will include AFA,s free ... and displays of the AFA Quilt to Remember. ...
(Date:2/22/2017)... Oncternal Therapeutics, Inc., a clinical-stage biotechnology ... common malignancies, today announced the closing of an ... to use the proceeds to further clinical development ... preclinical development of a new ROR1-targeted antibody-drug conjugate ... anti-ROR1 monoclonal antibody being developed to treat patients ...
(Date:2/22/2017)... NEW YORK , February 22, 2017 ... half of the 50 states in the U.S. have now legalized ... Brazil , Canada , ... , Portugal , Uruguay ... steps to legalize or decriminalize cannabis in the last two years. ...
Breaking Medicine Technology: